Meribank Biotech Co., Ltd
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was found… Read more
Meribank Biotech Co., Ltd (4724) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.092x
Based on the latest financial reports, Meribank Biotech Co., Ltd (4724) has a cash flow conversion efficiency ratio of 0.092x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$111.54 Million) by net assets (NT$1.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Meribank Biotech Co., Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Meribank Biotech Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Meribank Biotech Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Meribank Biotech Co., Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Black Iron Inc
PINK:BKIRF
|
0.136x |
|
Apollo Food Holdings Bhd
KLSE:6432
|
0.007x |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
0.070x |
|
Okong Corporation
KQ:045060
|
0.044x |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
-0.146x |
|
Modulight Oyj
HE:MODU
|
-0.010x |
|
Cytosorbents Corporation
F:HQE1
|
N/A |
|
Jeil Technos Co.Ltd
KQ:038010
|
0.019x |
Annual Cash Flow Conversion Efficiency for Meribank Biotech Co., Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Meribank Biotech Co., Ltd from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.22 Billion | NT$-38.09 Million | -0.031x | +29.30% |
| 2023-12-31 | NT$671.20 Million | NT$-29.70 Million | -0.044x | +49.27% |
| 2022-12-31 | NT$473.79 Million | NT$-41.33 Million | -0.087x | -122.31% |
| 2021-12-31 | NT$586.05 Million | NT$-23.00 Million | -0.039x | +15.35% |
| 2020-12-31 | NT$382.64 Million | NT$-17.74 Million | -0.046x | -438.32% |
| 2019-12-31 | NT$434.36 Million | NT$-3.74 Million | -0.009x | -- |